1. Home
  2. HHS vs LEXX Comparison

HHS vs LEXX Comparison

Compare HHS & LEXX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Harte-Hanks Inc.

HHS

Harte-Hanks Inc.

N/A

Current Price

$3.06

Market Cap

22.2M

ML Signal

N/A

Logo Lexaria Bioscience Corp.

LEXX

Lexaria Bioscience Corp.

HOLD

Current Price

$0.77

Market Cap

18.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HHS
LEXX
Founded
1923
2004
Country
United States
Canada
Employees
N/A
N/A
Industry
Advertising
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
22.2M
18.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
HHS
LEXX
Price
$3.06
$0.77
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$1.50
AVG Volume (30 Days)
10.1K
350.9K
Earning Date
03-16-2026
01-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$166,841,000.00
$522,000.00
Revenue This Year
$6.54
$13.35
Revenue Next Year
N/A
$78.83
P/E Ratio
N/A
N/A
Revenue Growth
N/A
5.05
52 Week Low
$2.33
$0.46
52 Week High
$5.54
$1.91

Technical Indicators

Market Signals
Indicator
HHS
LEXX
Relative Strength Index (RSI) 45.29 47.56
Support Level $2.92 $0.68
Resistance Level $3.15 $0.86
Average True Range (ATR) 0.15 0.07
MACD 0.01 0.02
Stochastic Oscillator 29.89 50.80

Price Performance

Historical Comparison
HHS
LEXX

About HHS Harte-Hanks Inc.

Harte-Hanks Inc is a customer experience company. The Company operates three business segments: Marketing Services; Customer Care; and Fulfillment & Logistics Services. The company has a geographic presence in the United States and Other countries. The majority of the revenue is earned from the United States.

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.

Share on Social Networks: